Equities

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

  • Revenue in USD (TTM)22.28bn
  • Net income in USD7.07bn
  • Incorporated1987
  • Employees10.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttp://www.gilead.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated2.83bn646.80m44.27bn2.30k69.3715.2460.3015.652.502.5010.9411.370.72363.348.801,230,054.0016.99-13.8321.87-18.1986.8989.6623.48-26.033.5914.490.1669--46.2010.26334.8852.4629.53--
Celgene Corporation14.73bn4.16bn48.59bn7.47k12.489.9910.253.305.573.9319.676.950.44661.037.481,972,278.0012.6210.5514.2911.8196.3595.7128.2523.631.99--0.80640.0015.8018.75110.5323.6511.71--
Allergan plc16.03bn-205.90m50.49bn17.80k--0.71597.313.15-0.57686.7147.72209.100.14222.435.69900,775.30-0.0725-3.28-0.0776-3.5686.3979.93-0.5102-26.440.77760.3910.2506--9.4021.93-457.69--45.77--
Biogen Inc13.23bn4.36bn64.43bn7.30k15.214.6811.624.8721.0215.4763.6068.330.5451.945.741,812,822.0018.6818.7021.6221.9086.1287.5234.2831.262.4736.510.30120.007.2117.340.267421.8949.69--
Bristol-Myers Squibb Co22.04bn4.38bn85.58bn23.70k19.616.2716.643.882.670.873113.468.360.65095.084.92929,831.3013.018.4718.2311.6770.8174.0919.9916.421.4042.190.34785.446.943.35-12.4314.7814.002.63
Gilead Sciences, Inc.22.28bn7.07bn87.60bn10.00k12.553.8310.223.935.401.2017.0017.670.34554.635.872,228,100.0011.0226.8513.0733.3479.6384.6031.8845.393.378.510.542812.47-14.0921.89-25.0431.328.24--
Eli Lilly And Co24.28bn2.36bn121.29bn40.66k50.359.5030.045.002.270.440223.4012.050.55411.525.24597,166.405.407.517.5110.2373.3975.099.7413.051.5369.630.472577.167.770.2359-37.54-16.0015.691.20
Amgen, Inc.23.32bn8.30bn125.01bn20.80k16.188.7612.255.3612.133.7133.9822.400.31581.376.811,121,106.0011.249.3913.0710.7182.5780.9635.6031.042.8418.340.705838.42-0.61765.764.6213.21-0.736526.15
Data as of Dec 12 2018. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

29.57%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201895.19m7.36%
Capital Research & Management Co. (Global Investors)as of 30 Sep 201869.85m5.40%
BlackRock Fund Advisorsas of 30 Sep 201866.45m5.14%
SSgA Funds Management, Inc.as of 30 Sep 201856.02m4.33%
Fidelity Management & Research Co.as of 30 Sep 201817.56m1.36%
Northern Trust Investments, Inc.as of 30 Sep 201816.61m1.28%
Dodge & Coxas of 30 Sep 201816.45m1.27%
Geode Capital Management LLCas of 30 Sep 201816.03m1.24%
T. Rowe Price Associates, Inc.as of 30 Sep 201814.55m1.13%
Capital Research & Management Co. (International Investors)as of 30 Sep 201813.75m1.06%
More ▼
Data from 30 Sep 2018 - 30 Sep 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.